India's DCGI halves clinical and marketing approval timelines, removes pre-clinical approval
Regulatory affairs teams at drug sponsors must file regulator-ready dossiers now
Change
India's Drug Controller General of India (DCGI) reduced clinical trial approvals to 120–135 days, cut marketing authorisation reviews to under 150 days, and removed the regulatory approval requirement at the pre-clinical stage.
Why it matters
Regulatory submissions will be processed under a compressed timeline that favours complete, regulator-ready files; incomplete submissions risk being routed into slower assessment tracks. Removing the pre-clinical approval gate transfers upfront compliance and documentation responsibility to sponsors and their quality teams before human trials begin.
Implications
- — Regulatory affairs teams at pharmaceutical and biotechnology sponsors and submission teams at contract research organisations (CROs) — must ensure dossiers and trial master files are fully complete and certified before filing immediately — incomplete filings will be deferred into slower processing tracks, delaying trial starts and marketing authorisations.
- — Legal and commercial teams with launch- or milestone-driven contracts for drugs seeking Indian approval — must revise launch timetables and milestone dates now — failure to align contracts with the new regulatory cadence risks missed contractual obligations or penalties tied to delayed approvals.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer